首页> Biochemical Pharmacology> The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-kappaB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats.

The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-kappaB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats.

导出原文传递

翻译打印收藏纠错

作者： Ochaion A ^[1] ; Bar-Yehuda S ; Cohen S ; Amital H ; Jacobson KA ; Joshi BV ; Gao ZG ; Barer F ; Patoka R ; Del-Valle L ; Perez-Liz G ; Fishman P

作者单位： Can-Fite BioPharma Ltd., Kiryat-Matalon, Petah-Tikva 49170, Israel. ^[1]

关键词 1-Phosphatidylinositol 3-Kinase Adenosine Animals Arthritis Rheumatoid 1-磷脂酰肌醇3-激酶腺苷动物关节炎类风湿疾病模型炎症

发布时间 2013-11-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Biochemical Pharmacology

2008年76卷4期

482-494页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

Biochemical Pharmacology

2008年76卷4期

482-494页

检索历史清除

The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-kappaB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats.

Biochemical Pharmacology

相似文献

Biochemical Pharmacology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-kappaB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats.

Biochemical Pharmacology

相似文献

Biochemical Pharmacology

相关期刊

检索历史清除